See more : Myriad Genetics, Inc. (0K3W.L) Income Statement Analysis – Financial Results
Complete financial analysis of Tissue Repair Ltd (TRP.AX) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Tissue Repair Ltd, a leading company in the Biotechnology industry within the Healthcare sector.
- Odessa Minerals Limited (ODE.AX) Income Statement Analysis – Financial Results
- Icosavax, Inc. (ICVX) Income Statement Analysis – Financial Results
- GVIC Communications Corp. (GCT.TO) Income Statement Analysis – Financial Results
- Ypsomed Holding AG (0QLQ.L) Income Statement Analysis – Financial Results
- Frontken Corporation Berhad (0128.KL) Income Statement Analysis – Financial Results
Tissue Repair Ltd (TRP.AX)
About Tissue Repair Ltd
Tissue Repair Ltd, a clinical stage biopharmaceutical company, developing advanced wound healing products for chronic wounds and the aftercare of cosmetic procedures in Australia. It is developing TR-987 and other dressing/matrices, including Glucoprime technology for the treatment of chronic wounds, burns, and other complex wounds; and TR Pro+ for aftercare of minimally invasive cosmetic procedures, as well as other products for veterinary, new bandage, scaffold products, and other therapeutic indications. The company was incorporated in 2012 and is headquartered in Sydney, Australia.
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Revenue | 152.24K | 3.08K | 171.92K | 152.64K | 156.00 |
| Cost of Revenue | 1.73K | 2.65K | 1.71K | 0.00 | 0.00 |
| Gross Profit | 150.51K | 428.00 | 170.21K | 152.64K | 156.00 |
| Gross Profit Ratio | 98.86% | 13.91% | 99.00% | 100.00% | 100.00% |
| Research & Development | 3.24M | 2.61M | 1.42M | 354.14K | 325.08K |
| General & Administrative | 2.39M | 2.23M | 1.87M | 227.71K | 92.53K |
| Selling & Marketing | 266.06K | 85.77K | 0.00 | 411.99K | 356.19K |
| SG&A | 2.65M | 3.13M | 1.87M | 639.70K | 448.72K |
| Other Expenses | 0.00 | 1.14M | -1.43M | 0.00 | 0.00 |
| Operating Expenses | 6.67M | 5.74M | 5.45M | 639.70K | 448.72K |
| Cost & Expenses | 6.67M | 5.74M | 5.45M | 639.70K | 448.72K |
| Interest Income | 743.38K | 430.16K | 39.78K | 1.18K | 156.00 |
| Interest Expense | 0.00 | 0.00 | 3.00 | 389.89K | 120.00 |
| Depreciation & Amortization | 1.73K | 2.65K | 1.71K | 488.53K | 448.56K |
| EBITDA | -6.51M | -5.14M | -7.01M | -189.44K | -52.19K |
| EBITDA Ratio | -4,279.15% | -186,530.56% | -3,976.17% | -419.10% | -287,641.03% |
| Operating Income | -4.88M | -5.74M | -6.84M | -639.70K | -448.72K |
| Operating Income Ratio | -3,202.81% | -186,616.71% | -3,977.17% | -419.10% | -287,641.03% |
| Total Other Income/Expenses | 737.85K | -373.89K | -2.79M | -579.34K | -52.15K |
| Income Before Tax | -4.14M | -5.14M | -6.84M | -1.07M | -500.87K |
| Income Before Tax Ratio | -2,718.15% | -167,197.43% | -3,977.17% | -699.61% | -321,067.95% |
| Income Tax Expense | 0.00 | -968.58K | -1.43M | -152.64K | -148.65K |
| Net Income | -4.14M | -4.17M | -6.84M | -915.23K | -352.21K |
| Net Income Ratio | -2,718.15% | -135,709.14% | -3,977.17% | -599.61% | -225,778.21% |
| EPS | -0.07 | -0.07 | -0.11 | -0.02 | -0.01 |
| EPS Diluted | -0.07 | -0.07 | -0.11 | -0.02 | -0.01 |
| Weighted Avg Shares Out | 60.46M | 60.46M | 60.46M | 41.33M | 41.33M |
| Weighted Avg Shares Out (Dil) | 60.46M | 60.46M | 60.46M | 41.33M | 41.33M |
Source: https://incomestatements.info
Category: Stock Reports